OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
zeannezg发布了新的文献求助10
1秒前
2秒前
岁岁平安完成签到,获得积分10
3秒前
世佳何完成签到,获得积分10
3秒前
zhang发布了新的文献求助10
4秒前
5秒前
Hello应助Eric采纳,获得10
5秒前
6秒前
zzwch完成签到,获得积分20
6秒前
积极以云发布了新的文献求助10
7秒前
yy发布了新的文献求助10
7秒前
月来越好发布了新的文献求助10
7秒前
promise发布了新的文献求助10
8秒前
zhang完成签到,获得积分10
9秒前
传奇3应助科研通管家采纳,获得10
9秒前
完美世界应助科研通管家采纳,获得10
9秒前
桐桐应助科研通管家采纳,获得10
10秒前
共享精神应助科研通管家采纳,获得10
10秒前
谢成勇完成签到,获得积分10
10秒前
lulu完成签到,获得积分10
11秒前
ykh完成签到,获得积分10
12秒前
zhangyixin发布了新的文献求助10
12秒前
12秒前
12秒前
甜美靖雁发布了新的文献求助10
12秒前
xiaoruiyao发布了新的文献求助10
13秒前
13秒前
13秒前
hoonie完成签到,获得积分10
14秒前
2522121033发布了新的文献求助10
14秒前
研友_VZG7GZ应助qiongqiong采纳,获得10
15秒前
xixixii发布了新的文献求助10
17秒前
乐乐应助令狐擎宇采纳,获得10
18秒前
完美的背包完成签到 ,获得积分10
21秒前
cvii完成签到,获得积分10
21秒前
skskysky应助追寻的问玉采纳,获得10
21秒前
洗月发布了新的文献求助30
21秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1500
Picture this! Including first nations fiction picture books in school library collections 1500
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
Scientific Writing and Communication: Papers, Proposals, and Presentations 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6370012
求助须知:如何正确求助?哪些是违规求助? 8184029
关于积分的说明 17265234
捐赠科研通 5424628
什么是DOI,文献DOI怎么找? 2869921
邀请新用户注册赠送积分活动 1847000
关于科研通互助平台的介绍 1693782